Please assess the completion status of the following clinical trial:

Trial Title: Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 and ≤ 80 years~* The diagnosis of ICH is confirmed by brain CT scan~* NIHSS score ≥6 and GCS \>6 upon presentation~* The first dose of the study drug is expected to be administered within 24h of ICH symptom onset~* Functional independence prior to ICH, defined as pre-ICH mRS ≤1~* Signed and dated informed consent is obtained.~Exclusion Criteria:~* Previous chelation therapy or known hypersensitivity to DFO products~* Known severe iron deficiency anemia (defined as hemoglobin concentration \< 7g/dL or requiring blood transfusions)~* Abnormal renal function, defined as serum creatinine \>2 mg/dL~* Planned surgical evacuation of ICH prior to administration of study drug (placement of a catheter for ventricular drainage is not a contraindication to enrollment)~* SUSPECTED secondary ICH related to tumour, ruptured aneurysm or arteriovenous malformation, hemorrhagic transformation of an ischemic infarct, or venous sinus thrombosis~* Infratentorial hemorrhage~* Irreversibly impaired brainstem function (bilateral fixed and dilated pupils and extensor motor posturing)~* Complete unconsciousness, defined as a score of 3 on item 1a of the NIHSS (Responds only with reflex motor or autonomic effects or totally unresponsive, and flaccid)~* Pre-existing disability, defined as pre-ICH mRS ≥2~* Coagulopathy - defined as elevated aPTT or INR \>1.3 upon presentation; concurrent use of direct thrombin inhibitors (such as dabigatran), direct factor Xa inhibitors (such as rivaroxaban or apixaban), or low-molecular-weight heparin~* Patients with confirmed aspiration, pneumonia, or evident bilateral pulmonary infiltrates on chest x-ray or CT scan prior to enrollment~* Patients with significant respiratory disease such as chronic obstructive pulmonary disease, pulmonary fibrosis, or any use (chronic or intermittent) of inhaled O2 at home~* FiO2 \>0.35 (\>4 L/min) prior to enrollment~* Sepsis (present source of infection ± lactic acidosis); Systemic Inflammatory Response Syndrome (Temp \>100.4F or \<96.8F; Heart rate \>90; Respiratory rate \>20 or PaCo2 \<32 mmHg; WBC \>12, \<4, or bands \>10%); or shock (SBP \<90 mmHg) at presentation~* The presence of 4 or more of the following risk modifiers for ARDS prior to enrollment:~  1. Tachypnea (respiratory rate \>30)~ 2. SpO2 \<95%~ 3. Obesity (BMI \>30)~ 4. Acidosis (pH \<7.35)~ 5. Hypoalbuminemia (albumin \<3.5 g/dL)~ 6. Concurrent use of chemotherapy~* Taking iron supplements containing ≥ 325 mg of ferrous iron, or prochlorperazine~* Patients with heart failure taking \> 500 mg of vitamin C daily~* Known severe hearing loss~* Known pregnancy, or positive pregnancy test, or breastfeeding~* Positive drug screen for cocaine upon presentation~* Patients known or suspected of not being able to comply with the study protocol due to alcoholism, drug dependency, noncompliance, living in another state or any other cause~* Any condition which, in the judgement of the investigator, might increase the risk to the patient~* Life expectancy of less than 90 days due to co-morbid conditions~* Concurrent participation in another research protocol for investigation of another experimental therapy~* Indication that a new DNR or Comfort Measures Only (CMO) order will be implemented within the first 72 hours of hospitalization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Deferoxamine Mesylate (Type: EXPERIMENTAL): Deferoxamine Mesylate (32 mg/kg/day) given by an intravenous infusion for 3 consecutive days
- Normal Saline (Type: PLACEBO_COMPARATOR): Normal saline (0.9% sodium chloride) given by intravenous infusion for 3 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).